---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-093961"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:40:10.680690+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Atea reports Q4 net loss $44.9M, cash $301.8M; HCV Phase 3 topline mid-2026; HEV program mid-2026

## Summary
- Net loss $44.9M in Q4 2025 (EPS -$0.57) vs $33.5M loss in Q4 2024; full-year net loss $158.3M.
- Cash and investments $301.8M at Dec 31, 2025, down from $454.7M a year ago.
- R&D expense $47.8M in Q4, up from $25.7M YoY, driven by HCV Phase 3 spend including milestone to Merck.
- Global Phase 3 HCV program: C-BEYOND (enrolled >880) topline mid-2026; C-FORWARD enrollment complete mid-2026, topline year-end 2026.
- Expanded antiviral pipeline: HEV program with AT-587 expected to enter clinic mid-2026; presented in vitro data at CROI 2026.

## SEC filing metadata
- accession: 0001193125-26-093961
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312526093961/0001193125-26-093961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312526093961/d118938d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-093961
- JSON: https://secwatch.observer/filing/0001193125-26-093961.json
- Plain text: https://secwatch.observer/filing/0001193125-26-093961.txt

## Key facts
- Earnings Releases
  Atea Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1593899/000119312526093961/0001193125-26-093961-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.